China Special Interest Group launch
This event is now full.
Join us to learn about the new China Biotech Special Interest Group (SIG), gain insight from companies with experience in China, and how you can become involved.
The China Biotech SIG has been set up with the China-Britain Business Council (CBBC), and supported by the Department for International Trade (DIT), to provide a discussion platform for BIA and CBBC members in the Biotech sector, exploring the opportunities for business growth in and with China, via trade and investment.
The group is open to BIA and CBBC members only. The event is free of charge, however please register as there is limited capacity.
China-Britain Business Council
3rd Floor, Portland House
15.00: Registration and networking
15.30: Introducing the Special Interest Group: BioIndustry Association (BIA), China Britain Business Council (CBBC), and Department of International Trade (DIT)
15.40: Why China, why now? Political and economic factors making China a viable opportunity for biotech, and the challenges that prevail: Andy Richards, Serial Biotechnology Entrepreneur and Business Angel, Congenica
BIA member case studies:
15.50: Selling and expanding into China: Oxford Nanopore Technologies
16.00: Research and collaboration, Innovate UK, Cell and Gene Therapy Catapult
16.20: Challenges and opportunities in early stage investment, Kymab
Overview and discussion:
- 16.40: Current and future life science trends in China, McKinsey & Company, Inc
- 16.50: Discussion and establishing future objectives of the China Special Interest Group
17.00: Drinks and networking
Dr Andy Richards
Andy has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, and Cancer Research Technology (commercial arm of CR-UK. He is an advisor to Cambridge Innovation Capital and the UCL Technology Fund.
His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels.
Dr Hidetoshi Hoshiya
Hidetoshi Hoshiya is the Transaction manager -Asia & Oceania of the Cell and Gene Therapy Catapult. His role is to develop and implement the Cell and Gene Therapy Catapult’s Asian and Oceanian Strategy by identifying, qualifying and transacting deals with Asian and Oceanian organisations. He supports mutual access of industries between UK and Asia/Oceania.
Previously he was a research associate at the University College London in the UK and the San Raffaele Scientific Institute in Italy.
He holds a PhD in Regenerative Medicine from the Tottori University.
Global Innovation Lead & Horizon 2020 National Contact Point - Health, Innovate UK
Jerome is the Global Innovation Lead for Health & Horizon 2020 National Contact Point at Innovate UK and is mainly responsible to help UK applicants to the Horizon 2020 Health opportunities, input into the content of the calls published under the Health Challenge as a member of the UK H2020 Programme Committee delegation, and support Innovate UK’s international strategy.
In his previous position, he was overlooking the evaluation and progress of a portfolio of >100 research & innovation projects across Europe for the Active Assisted Living programme (AAL Programme), a EU funding initiative supporting ICT for Active and Health Ageing.
Jerome joined Innovate UK in Jan 2015.
Qualified Chartered Accountant with 25 years experience of senior financial positions in UK and US listed companies, as well as a range of startups and AIM listed Companies. Considerable experience in an executive capacity of IPO’s and M&A, as well as non-exec directorships in Bioventix Plc and Clipper Ventures Plc.
Listed companies include Celltech Plc, British Biotech Plc, and Vernalis Plc. Joined Oxford Nanopore in 2012 as Commercial Operations Director, to set up operations appropriate to grow the business in the early years and moved back to Finance in 2017.